Search Results
Article Topics
Your search for all items matches 22208 pages
Showing 51 - 100Expert Point of View: Don S. Dizon, MD, FACP, FASCO
Commenting on the SOLO2 trial for The ASCO Post was Don S. Dizon, MD, FACP, FASCO, Director of Women’s Cancers at Lifespan Cancer Institute and Professor of Medicine at Brown University, Providence, Rhode Island. “It’s great to get an overall survival advantage from a PARP inhibitor study. Coming...
Overall Survival Benefit Shown for Maintenance Olaparib in Ovarian Cancer
For the first time, overall survival has been improved with maintenance therapy involving a poly (ADP-ribose) polymerase (PARP) inhibitor in patients with platinum-sensitive recurrent ovarian cancer associated with BRCA1/2 mutations. In the final, preplanned, overall survival analysis in the...
Study Finds Cancer-Related Deaths Declined in States With Expanded Access to Medicaid
States that adopted Medicaid expansion after passage of the Affordable Care Act (ACA) in 2010 saw a decline in cancer mortality rates by 29% compared with 25% in states that did not expand access to Medicaid, according to a study by Anna Lee, MD, MPH, of Memorial Sloan Kettering Cancer Center, New...
Cancer vs COVID-19: Clinical Trial Research During the Pandemic
The COVID-19 pandemic transformed cancer care, seemingly overnight, as practices scrambled to ensure a safe environment for caregivers and patients. Although regulatory burdens have been relaxed to allow patients to continue on trial treatment and telemedicine has expanded its competency and reach, ...
How the Lung Cancer Community Came Together During the COVID-19 Pandemic
The COVID-19 pandemic (caused by infection with the SARS-CoV-2 coronavirus) has created a host of diagnostic, treatment, and follow-up problems for patients with cancer of all types, and this is particularly true for patients with lung cancer, their families, and providers. Everyone wanted to...
Spartalizumab for Locally Advanced or Metastatic Anaplastic Thyroid Carcinoma
In a phase II study reported in the Journal of Clinical Oncology, Jaume Capdevila, MD, and colleagues found that the programmed cell death protein 1 (PD-1) inhibitor spartalizumab produced responses in a cohort of patients with locally advanced or metastatic anaplastic thyroid carcinoma, with all...
Byoung Chul Cho, MD, PhD, on NSCLC: Genetic Mutations and Immunotherapy vs Chemotherapy in KEYNOTE-042
Byoung Chul Cho, MD, PhD, of Yonsei Cancer Center and Severance Hospital, discusses the STK11 and KEAP1 mutations in non–small cell lung cancers, and their relationship to the efficacy of pembrolizumab monotherapy vs platinum-based chemotherapy as first-line treatment for PD-L1–positive advanced...
Highlights From the AACR Virtual Annual Meeting
This week, we’ll be featuring some research highlights from the AACR Virtual Annual Meeting, including data on a triplet regimen for women with high-risk, HER2-negative breast cancer; findings on immunotherapy combined with targeted therapy for patients with BRAF V600-mutated melanoma; and a paper...
Mikkael A. Sekeres, MD, on Cancer Treatment in the Age of COVID-19: Personal Observations
Mikkael A. Sekeres, MD, of the Cleveland Clinic, talks about the ways in which social distancing and viral fears have affected the way he delivers treatment for his patients, as well as the effect on their psyches—and his. Recorded April 10, 2020.
Expert Point of View: Charles L. Sawyers, MD
Charles L. Sawyers, MD, of Memorial Sloan Kettering Cancer Center, New York, commented on the SWOG S1320 study presented at the 2020 American Association for Cancer Research Virtual Annual Meeting. “Intermittent therapy is standard with chemotherapy due to toxicity, but targeted therapies...
AACR 2020: Continuous Dosing of Dabrafenib Plus Trametinib Improves Progression-Free Survival vs Intermittent Dosing in Advanced Melanoma
Continuous dosing with dabrafenib and trametinib improved progression-free survival in patients with BRAF-mutated advanced melanoma compared with an intermittent-dosing strategy, according to results of the phase II SWOG S1320 randomized trial reported at the opening Plenary Session of the 2020...
Don’t Touch Me With a 6-Foot Pole
The universe has an intriguing way of registering our wishes and delivering them in convoluted, mutated forms. Last winter, I recall coming home after a long day at the hospital and being ambushed by my 3-year-old daughter and preteen son. She wanted to play, he needed help with homework, and they ...
Can Communication Skills Training for Oncologists Improve Discussion of Goals of Care for Patients With Advanced Cancer?
In a study reported in JCO Oncology Practice, Bickell et al found that providing oncologists with communication skills training did not improve the frequency or quality of goals-of-care discussions for patients with advanced cancer. Study Details In the study, 22 oncologists were randomly assigned...
Ruxolitinib in Glucocorticoid-Refractory Acute Graft-vs-Host Disease After Stem Cell Transplant
In the phase III REACH2 trial reported in The New England Journal of Medicine, Zeiser et al found that the JAK1/2 inhibitor ruxolitinib improved response rate vs investigator’s choice of therapy in patients with glucocorticoid-refractory acute graft-vs-host disease (GVHD) following allogeneic stem...
Can a Culturally Tailored Education Program Improve Colorectal Cancer Awareness and Screening?
People who received information from the Screen to Save program, a culturally tailored initiative from the National Cancer Institute (NCI) Center to Reduce Cancer Health Disparities (CRCHD), increased their knowledge of colorectal cancer and indicated willingness to adopt potentially preventive...
Half of Surveyed Cancer Researchers Report Their Work Is on Hold Due to the COVID-19 Pandemic
A survey of American Cancer Society grantees found that about half reported their cancer research has been halted as a result of the COVID-19 pandemic. The American Cancer Society reached out to all of its funded researchers to assess the state of their projects and collect information to guide...
FDA Approves Selpercatinib for Lung and Thyroid Cancers With RET Mutations or Fusions
On May 8, 2020, the U.S. Food and Drug Administration (FDA) granted accelerated approval to selpercatinib (Retevmo) for the following indications: Adult patients with metastatic RET fusion–positive non–small cell lung cancer (NSCLC) Adult and pediatric patients ≥ 12 years of age with advanced or...
In ‘Remembering Mum,’ Siblings Honor Their Mother With Action and Innovation
It’s one of the worst things Claire Paxman can recall: She’s 14 years old, using orange-handled kitchen scissors to cut her mother’s hair. “You shouldn’t be standing in the bathroom cutting your mom’s hair because of chemotherapy,” said Claire as she describes that defining childhood moment when ...
Financial Support Available to Providers During COVID-19 Pandemic
The Coronavirus Aid, Relief, and Economic Security (CARES) Act and new guidance from the Centers for Medicare & Medicaid Services (CMS) both contain provisions to provide financial support to qualified providers. ASCO strongly encourages providers to immediately begin meticulously documenting...
ASCO’s COVID-19 Cancer Registry Aims to Understand Impact on Patients During Pandemic, Inform Future Care
ASCO has launched the ASCO Survey on COVID-19 in Oncology Registry (ASCO Registry) to help the entire cancer community learn about the pattern of symptoms and severity of COVID-19 among patients with cancer, as well as how COVID-19 infections impact the delivery of cancer care and patient outcomes. ...
COVID-19: What People With Cancer Need to Know
Encourage your patients and their caregivers to visit the award-winning Cancer.Net Blog for key information from leading experts for people with cancer and cancer survivors about the COVID-19 pandemic. COVID-19 content is also available in Spanish. Help keep your patients informed by directing...
Scott Kopetz, MD, PhD, FACP: Breakthroughs in Combination Therapy for Colorectal Cancer
Scott Kopetz, MD, PhD, FACP, works to improve outcomes for patients with colorectal cancer at The University of Texas MD Anderson Cancer Center. The trial: Single drugs aimed at inhibiting the BRAF gene have not been effective against BRAF-mutated colorectal cancers. To explore the effectiveness...
My ASCO Journey: Opportunities for Gratitude and Breaking Glass Ceilings
In my native language, there is a saying that is translated as, “A child who does not travel only appreciates their mother’s cooking.” In the broad sense, as we grow up and experience the different things that life has to offer, two things happen if we allow our minds to open up: we realize there...
Ongoing Efforts Toward Vaccine Development for COVID-19
Coronavirus disease 2019 (COVID-19) is spreading throughout the world, and vaccine developers have responded with unprecedented speed. Since the COVID-19 genome sequence was released in January, human trials of an experimental vaccine candidate have already begun in the Seattle area. Although the...
I Have Multiple Myeloma and Am Concerned About the Coronavirus
In hindsight, the symptoms I began experiencing in the fall of 2013—sudden excruciating back bone pain and severe fatigue—should have tipped me off that I had a serious disease, but 7 years ago, they were easy to explain away. The bone pain was similar to what I had experienced several years...
Yoga for Pediatric and Adolescent Patients With Cancer
The ASCO Post’s Integrative Oncology series is intended to facilitate the availability of evidence-based information on integrative and complementary therapies sometimes used by patients with cancer. Despite significant improvements reported in survival rates, symptom management in pediatric...
Global COVID-19 Observatory and Resource Center for Childhood Cancer
St. Jude Children’s Research Hospital, in partnership with the International Society of Paediatric Oncology (SIOP), has launched the Global COVID-19 Observatory and Resource Center for Childhood Cancer. The website offers health-care providers around the world a space to share the latest...
Breast Surgeon Kristin L. Brill, MD, Joins Sidney Kimmel Cancer Center
Kristin L. Brill, MD, has joined the Sidney Kimmel Cancer Center–Jefferson Health (SKCC) in Philadelphia as Enterprise Director of Breast Oncology. Dr. Brill brings expertise in a comprehensive range of services for patients with malignant and benign diseases, including breast-conserving surgery,...
Larry Kwak, MD, PhD, Named AIMBE Fellow
City of Hope recently announced that Larry Kwak, MD, PhD, has been inducted into the 2020 Class of American Institute for Medical and Biological Engineering (AIMBE) Fellows. Dr. Kwak is Vice President and Deputy Director of City of Hope’s Comprehensive Cancer Center. He has pioneered breakthrough...
Aria Vaishnavi, PhD, Receives NCI’s Pathway to Independence Award
Aria Vaishnavi, PhD, a postdoctoral fellow at the Huntsman Cancer Institute at the University of Utah, has received the first annual National Cancer Institute (NCI) Pathway to Independence Award for Outstanding Early Stage Postdoctoral Researchers (K99/R00). The “Early K99” grant supports...
Fox Chase Cancer Center Welcomes Andres F. Correa, MD
Fox Chase Cancer Center announced that Andres F. Correa, MD, has joined the Department of Surgery in the Urologic Oncology Division as Assistant Professor. Dr. Correa, w ho was a Society of Urologic Oncology Fellow at Fox Chase, is returning to the center after serving as Attending Surgeon and...
Parker Institute for Cancer Immunotherapy Appoints Frederic Pla, PhD, as Chief Operating Officer
The Parker Institute for Cancer Immunotherapy (PICI) recently announced the appointment of Frederic Pla, PhD, as its Chief Operating Officer (COO). Dr. Pla will lead day-to-day operations and work with the Institute’s leadership team to establish goals for performance, expansion, and sustainable...
Durvalumab Plus Chemotherapy for Extensive-Stage Small Cell Lung Cancer
On March 27, 2020, durvalumab (Imfinzi) was approved for use in combination with etoposide and either carboplatin or cisplatin as first-line treatment of patients with extensive-stage small cell lung cancer.1,2 Supporting Efficacy Data Approval was based on the findings of the open-label phase III ...
Grace and Forgiveness
The ASCO Post is pleased to reproduce installments of the Art of Oncology as published previously in the Journal of Clinical Oncology. These articles focus on the experience of suffering from cancer or of caring for people diagnosed with cancer, and they include narratives, topical essays,...
Encorafenib Combined With Cetuximab in Previously Treated BRAF V600E–Mutant Metastatic Colorectal Cancer
On April 8, 2020, encorafenib was approved for use in combination with cetuximab for the treatment of previously treated adult patients with metastatic colorectal cancer with a BRAF V600E mutation detected by a U.S. Food and Drug Administration (FDA)-approved test.1,2 Encorafenib is not indicated...
Understanding Patient-Reported Outcomes in Cancer Trials: A Beginner’s Guide
Patient-reported outcomes are measures used in clinical trials to capture aspects of a patient’s health condition, reported directly by the patient, without introduction of bias from third parties. They are distinct from the physical toxicities reported by clinicians1 and are collected using a...
The Role of Adipose Tissue in Cancer Aggressiveness
Over the past decade, obesity has been linked to an increased risk and aggressiveness of numerous cancer types. Many biologic activities within adipose tissue change with obesity and may contribute to carcinogenesis and the initiation of cancer. To shed light on the current state of knowledge in...
Highlights From ASH 2019 Included New Data in Leukemia, Lymphoma, Myeloma, and Myelodysplastic Syndromes
The 2019 American Society of Hematology (ASH) Annual Meeting & Exposition featured a cornucopia of sessions. It was impossible to attend all the lectures, symposia, oral presentations, poster presentations, and special events because many were concurrent. Below, we have selected some...
American Cancer Society Awards New Research, Training Grants
The American Cancer Society (ACS) has approved funding for 79 research and training grants, totaling $36,165,100 in the first of two grant cycles for 2020. Grant applications were reviewed and approved remotely in light of the coronavirus epidemic. The grants will fund investigators at 59...
Pooled Analysis Supports Benefit of Dual HER2-Targeted Therapy, but Questions Remain
In the treatment of HER2-positive early breast cancer, patients who receive dual HER2-targeted therapy in both the neoadjuvant and adjuvant settings are less likely to experience recurrence than those who received dual therapy only as neoadjuvant treatment, according to a pooled analysis of...
KEYNOTE-522: A Biomarker Resource for PD-1 Inhibition in Early Triple-Negative Breast Cancer
In the phase III KEYNOTE-522 trial reported in The New England Journal of Medicine and reviewed in this issue of The ASCO Post, Schmid et al1 found that the addition of pembrolizumab to neoadjuvant chemotherapy in stage II or III triple-negative breast cancer significantly improved the pathologic...
Neoadjuvant and Adjuvant Pembrolizumab Improves Outcomes in Early Triple-Negative Breast Cancer
As reported in The New England Journal of Medicine by Peter Schmid, MD, PhD, of Barts Cancer Institute, Queen Mary University of London, and colleagues, analyses in the phase III KEYNOTE-522 trial have shown that the addition of pembrolizumab to neoadjuvant chemotherapy and the use of adjuvant...
Expert Point of View: Virginia Kaklamani, MD, DSc, and Minetta Liu, MD
Virginia Kaklamani, MD, DSc, Professor of Medicine and Head of the Breast Cancer Program at UT Health San Antonio MD Anderson Cancer Center, moderated a press conference where Milan Radovich, PhD, reported the robust ability of circulating tumor DNA (ctDNA) and circulating tumor cells to predict...
Studies Show Circulating Tumor Material May Predict Outcomes After Neoadjuvant Therapy for Breast Cancer
In early triple-negative breast cancer, the presence of circulating tumor DNA (ctDNA) and circulating tumor cells after neoadjuvant chemotherapy may enable risk stratification of patients for disease recurrence and may predict outcomes, according to a preplanned correlative analysis of the phase II ...
Expert Point of View: Basem M. William, MD, MRCP (UK), FACP, and Caron Jacobson, MD
Basem M. William, MD, MRCP (UK), FACP, Director of the T-Cell Lymphoma Program and Member of the Blood and Marrow Transplant Program at The Ohio State University Comprehensive Cancer Center, Columbus, said many of the new-generation bispecific antibodies are “highly promising.” He said they “are...
Bispecific Antibodies Poised to Impact Treatment of Lymphoma and Other Blood Cancers
Studies of second-generation bispecific antibodies were among the highlights of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition. The bispecific T-cell engager blinatumomab was the first such agent to be approved by the U.S. Food and Drug Administration (FDA) in...
Actively Recruiting Clinical Trials Studying Cancer Prevention Measures
This Clinical Trials Resource Guide lists actively recruiting clinical trials evaluating strategies to improve cancer prevention measures, mostly through increased rates of screening. Some of the following trials also address cancer prevention through improving knowledge of tumor biomarkers,...
Addition of Pembrolizumab to Docetaxel for Previously Treated Immunotherapy-Naive Patients With Advanced Lung Cancer
In the single-institution phase II PROLUNG trial reported in JAMA Oncology, Oscar Arrieta, MD, and Christian Rolfo, MD, PhD, and colleagues found that the addition of pembrolizumab to docetaxel improved objective response rates and progression-free survival in immunotherapy-naive patients with...
Addition of Olaparib to Bevacizumab Maintenance in Advanced Ovarian Cancer: PAOLA-1 Trial
As reported in The New England Journal of Medicine by Isabelle Ray‑Coquard, MD, PhD, of the Centre Leon Berard, University Claude Bernard Lyon 1 and Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens (GINECO), Paris, and colleagues, the phase III PAOLA-1 trial has shown a...
Joint Guideline Sheds Light on Management of Hereditary Breast Cancer
As germline genetic testing becomes more widespread among patients with breast cancer, recommendations for the appropriate management of patients with hereditary breast cancer are needed. Until now, no ASCO guideline has addressed the management of hereditary breast cancer, even for carriers of...
